drugset / Trial / NCT01808820
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.
Timeline
- Start
- 2013-08-21
- Primary completion
- 2018-11-07
- Completion
- 2022-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | 1.2e+06 cells | Intramuscular |
| Subject | DC vaccine | Vaccine | 1.2e+07 cells | Intramuscular |
| Subject | Tumor Lysate | Unknown | 1.5 mg | Intramuscular |
| Background | Imiquimod | Other / unclassified | 5 % | Topical |